The GLP-1 cycle-off protocol: preserving muscle and facial volume with GH-releasing peptides.

The documented lean-mass cost of GLP-1 therapy

Let's start with what the data actually shows, because the fitness and aesthetics industries have been dancing around it. The STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity and randomized them to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks [1]. Mean total body weight loss in the semaglutide group was 14.9%. Of that weight loss, approximately 39% was lean mass — not fat. That is not a rounding error. For someone who loses 20 kg on semaglutide, roughly 7–8 kg of that is lean tissue.

SURMOUNT-1, the tirzepatide phase 3 trial published in 2022, showed better total weight loss (averaging 20%+ at the highest dose), and the lean-mass proportion was somewhat lower — approximately 25% of total weight lost was lean mass [2]. This is better than semaglutide on that metric, but still represents a meaningful lean-tissue deficit at the weight-loss magnitudes tirzepatide produces. Someone losing 25 kg on tirzepatide at maximum dose could expect to lose 6+ kg as lean mass.

Lean mass in this context includes skeletal muscle — and it includes the subdermal fat and soft tissue structures that maintain facial volume and skin laxity. The "GLP-1 face" that aesthetics practitioners have been describing since 2023 is not a side effect that happens to some users. It is a predictable outcome of losing 20–40% of your weight-loss total as lean and soft tissue, concentrated in the face where volume loss is most perceptible. The trials documented this. The prescribers mostly didn't discuss it.

The GLP-1 lean-mass cost is not a rumor or a fringe concern. It is documented in the phase 3 trials, in the published body composition sub-analyses. The question is what to do about it — not whether it happens.

Why GH-releasing peptides, not exogenous HGH

The instinct for many people coming off GLP-1s and wanting to preserve or rebuild lean mass is to reach for growth hormone — specifically recombinant human growth hormone (HGH), which is prescribed for GH deficiency and has an established black-market presence in the body-optimization community. This is the wrong tool for this application, and the reason is pulsatility.

Endogenous GH is not secreted tonically. It is released in discrete pulses — primarily overnight, during deep sleep, and in response to exercise — driven by growth hormone-releasing hormone (GHRH) from the hypothalamus and amplified by ghrelin and related peptides. The pulse amplitude and frequency decline with age, which is a key driver of the age-related decline in lean mass, skin quality, and metabolic rate. This is the signal that GH-releasing peptides are designed to restore.

Exogenous HGH bypasses this system entirely. Daily subcutaneous HGH creates tonic, non-pulsatile GH exposure. This suppresses the pituitary's own GH production (because the hypothalamic-pituitary feedback loop reads "GH is present, stop releasing GHRH and ghrelin") and disrupts the feedback mechanism that normally prevents GH from chronically elevating IGF-1 (insulin-like growth factor 1) above the physiologic range. Chronically supraphysiologic IGF-1 is associated with concerns around cancer risk and insulin resistance that do not apply at the same magnitude to pulsatile GH stimulation.

GH-releasing peptides preserve the feedback loop. They stimulate the pituitary to release GH in pulses — which means the downstream IGF-1 signal remains within the physiologic envelope. When you stop taking GH-releasing peptides, your own GH production recovers to baseline within days to weeks because the pituitary was never suppressed. When you stop exogenous HGH, you may face a period of suppressed endogenous GH — which is the opposite of the goal in a post-GLP-1 lean-mass recovery protocol.

The cost advantage is also real: GH-releasing peptides obtained through compounding pharmacies (where prescribed) typically run $150–300/month versus $400–1,200/month for pharmaceutical HGH at equivalent GH-stimulating doses. The pharmacoeconomic argument reinforces the biological one.

CJC-1295 without DAC + ipamorelin: the signal they pull and why

CJC-1295 without DAC (also called modified GRF 1-29, or mod-GRF 1-29) is a synthetic analogue of GHRH — the 29-amino-acid sequence that the hypothalamus releases to signal the pituitary to release GH. The "without DAC" designation is critical: it means the peptide does not contain the Drug Affinity Complex that extends its half-life by binding to albumin. CJC-1295 without DAC has a half-life of approximately 15–30 minutes, which means it mimics a natural GHRH pulse rather than creating prolonged tonic GHRH stimulation. The version with DAC has a half-life of approximately 6–8 days and creates sustained GHRH signaling — the opposite of what you want for preserving pulsatility.

Ipamorelin is a pentapeptide GHRP (growth hormone-releasing peptide) — a ghrelin mimetic that binds the ghrelin receptor (also called GHSR-1a, the growth hormone secretagogue receptor) on pituitary somatotrophs and stimulates GH release through a separate mechanism from GHRH. When used in combination, CJC-1295 without DAC provides the GHRH signal (amplitude) and ipamorelin provides the GHSR signal (pulse trigger) — the two signals are synergistic, producing a larger GH pulse than either compound alone.

Ipamorelin's key advantage over older GHRPs like GHRP-2 or GHRP-6 is selectivity: it stimulates GH release without meaningfully elevating cortisol or prolactin at therapeutic doses — the off-target effects that made earlier GHRPs harder to use cleanly [3]. This selectivity is documented in preclinical models; human clinical data on ipamorelin's cortisol and ACTH profile specifically is limited. It remains the main reason ipamorelin displaced GHRP-6 as the preferred GHRP pairing in clinical GH optimization work.

The net signal they pull: a physiologic, pulsatile GH release that drives modest increases in IGF-1, promotes protein synthesis and nitrogen retention in skeletal muscle, supports lipolysis (preferentially targeting visceral adipose tissue), and improves sleep architecture via GH's role in delta-wave sleep. All of this occurs while preserving the pituitary's own feedback sensitivity.

Fragment 176-191 and AOD-9604: what they do and don't do in this context

Both Fragment 176-191 and AOD-9604 come up constantly in post-GLP-1 and body-recomposition discussions, and both are routinely overclaimed. Here is the honest version.

AOD-9604 is a synthetic peptide derived from the C-terminal fragment of the human growth hormone molecule — specifically the 177-191 amino acid sequence, modified with a tyrosine residue at position 177 for stability. It was developed by Monash University and Metabolic Pharmaceuticals with the explicit goal of isolating the lipolytic activity of HGH without the IGF-1-elevating and glucose-dysregulating effects of full-length HGH. It went through six human clinical trials — more than most research peptides ever see. The preclinical lipolytic mechanism is documented in Heffernan et al. [4]. The clinical development program showed a favorable safety profile (no IGF-1 elevation, no glucose disruption), but the fat-loss effect sizes did not justify pharmaceutical development, and Metabolic Pharmaceuticals ceased the program. The Phase IIb results were reported in clinical regulatory filings but not published as a peer-reviewed primary paper — a gap worth noting when evaluating community-use claims about the compound.

Fragment 176-191 is a different peptide — the 176-191 amino acid sequence of HGH without the tyrosine modification — that is widely sold as a research chemical and has essentially no published human clinical trial data of its own. What gets attributed to it in community use is largely extrapolated from the AOD-9604 data. They are structurally related but not identical, and the evidence base for Fragment 176-191 specifically is thin.

In the context of a post-GLP-1 lean-mass recovery protocol, both compounds have a narrow and honest role: modest additional lipolytic support, particularly for visceral fat, without the concerns around IGF-1 elevation that would apply to full-length HGH or high-dose GHRH analogues. They are not muscle-builders. They do not stimulate protein synthesis. They do not address the lean-mass deficit from GLP-1 use. For that problem, CJC-1295 + ipamorelin is the right tool. Fragment 176-191 and AOD-9604 are, at best, adjuncts for additional fat metabolism support — not the primary lever.

The 12-week post-GLP-1 framework

This is a framework, not a prescription. It is a structure to bring to a clinician who is literate in peptide pharmacology and can evaluate it against your specific labs, history, and goals. Note: CJC-1295 (no DAC) and ipamorelin are not FDA-approved drugs; their use in this context is off-label and unregulated in the United States and most other jurisdictions. With that established clearly:

The facial volume question

Facial volume loss during GLP-1 therapy is driven by a combination of subdermal fat loss, reduced soft tissue volume, and in some cases skin laxity from rapid weight change. GH-releasing peptides address the systemic lean-mass component but are not a specific facial intervention. The route for facial volume restoration in post-GLP-1 patients in clinical practice runs through dermal fillers, autologous fat transfer, and collagen-stimulating treatments — not through systemic peptide protocols.

What the GH-pulsatile signal does contribute: it supports collagen synthesis systemically, which improves skin quality and elasticity at the structural level over 12+ weeks. This is a real but diffuse effect — it will not replace specific volume lost from the midface or temples, but it creates a better tissue substrate for whatever aesthetic interventions the patient pursues. The clinician managing the GLP-1 cycle-off should ideally be in communication with the aesthetics provider managing facial volume.

For a more complete picture of the GLP-1 lean-mass and body composition literature, see the existing Wellness Radar coverage on GLP-1s and the lean-mass problem and GLP-1 weight regain after discontinuation.

Who should not attempt this protocol

GH-releasing peptides are not universally appropriate, and the conditions that contraindicate them are worth naming directly:

• Active malignancy or unscreened cancer risk: The GH/IGF-1 axis is a recognized growth factor pathway for several cancer types. Anyone with an active malignancy or a first-degree family history of IGF-1-sensitive cancers (colorectal, breast, prostate) should have thorough screening and an oncologist-aware clinician before initiating any GH secretagogue protocol. I am not telling anyone to take these compounds — I am saying that if you are going to, this conversation needs to happen first.
• Untreated diabetic retinopathy: GH elevation can acutely worsen diabetic retinopathy. Anyone with active retinal disease from diabetes should not use GH-releasing peptides without explicit ophthalmologic clearance.
• Uncontrolled hypertension: Fluid retention is a known effect of GH activation, particularly in the early weeks of a protocol. Uncontrolled hypertension is an absolute contraindication until the blood pressure picture is managed.
• Pregnancy or lactation: No safety data exists. Full stop.
• Acromegaly or pituitary adenoma history: Obvious contraindication to anything that stimulates pituitary GH output.

Going deeper

This article covers the framework at the level appropriate for an informed starting point. The peptide-specific detail — receptor binding kinetics, dose-response data for GHRPs, the pharmacokinetic differences between CJC-1295 with and without DAC, the full GH secretagogue evidence base including sermorelin and tesamorelin — lives in the Wellness Radar Peptide Manual.

The Manual goes beyond what any single article can responsibly cover: 50 deep peptide profiles, 40 bioregulator entries, complete dosing tables, stack architecture, and the full GLP-1/GH-peptide framework laid out across chapters. If you are serious about this space, that is where the depth lives.